211-astatine mx35 f(ab')2
mAbexperimentalADC
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 5, 2005 (NCT04461457)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
SLC34A2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 211-Astatine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04461457 | Early Phase 1 (Phase 1) | Feb 5, 2005 | Swedish Cancer Society, The Swedish Research Council, University of Gothenburg, Vastra Gotaland Region |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Swedish Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2005 |
| The Swedish Research Council | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Gothenburg | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Vastra Gotaland Region | Government | 1 | 1 | 1 | 2005 |
4 organizations
Page 1 / 1